知名投资机构Canaccord Genuity于7月15日发布最新评估报告，将器官移植医疗技术公司TransMedics集团（TMDX）的目标股价从每股129美元大幅调升至142美元。此次上调幅度达10%，反映出该机构对TransMedics在器官转运系统领域技术优势的持续看好。
分析师在报告中指出，器官移植医疗设备的市场需求正呈现加速增长态势。随着全球器官移植手术量突破历史峰值，TransMedics旗下经FDA认证的便携式灌注系统展现出强劲的商业化潜力。该设备通过维持离体器官生理活性，显著延长器官转运时间窗，成功解决传统低温运输的技术瓶颈。
二级市场数据显示，TransMedics股价在过去三个季度累计上涨47%，跑赢同期医疗器械板块26个百分点。此次目标价上调后，该股潜在上涨空间较当前交易价仍保持双位数增长预期。值得注意的是，公司最新季报显示其营收同比增长率达89%，器官转运系统装机量在北美主要移植中心覆盖率已突破75%关键节点。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.